Your browser doesn't support javascript.
loading
Gene therapy: is IL2RG oncogenic in T-cell development?
Pike-Overzet, Karin; de Ridder, Dick; Weerkamp, Floor; Baert, Miranda R M; Verstegen, Monique M; Brugman, Martijn H; Howe, Steven J; Reinders, Marcel J T; Thrasher, Adrian J; Wagemaker, Gerard; van Dongen, Jacques J M; Staal, Frank J T.
Afiliação
  • Pike-Overzet K; Department of Immunology, Erasmus University Medical Center, 3015 GE Rotterdam, The Netherlands.
Nature ; 443(7109): E5; discussion E6-7, 2006 Sep 21.
Article em En | MEDLINE | ID: mdl-16988660
ABSTRACT
The gene IL2RG encodes the gamma-chain of the interleukin-2 receptor and is mutated in patients with X-linked severe combined immune deficiency (X-SCID). Woods et al. report the development of thymus tumours in a mouse model of X-SCID after correction by lentiviral overexpression of IL2RG and claim that these were caused by IL2RG itself. Here we find that retroviral overexpression of IL2RG in human CD34+ cells has no effect on T-cell development, whereas overexpression of the T-cell acute lymphoblastic leukaemia (T-ALL) oncogene LMO2 leads to severe abnormalities. Retroviral expression of IL2RG may therefore not be directly oncogenic--rather, the restoration of normal signalling by the interleukin-7 receptor to X-SCID precursor cells allows progression of T-cell development to stages that are permissive for the pro-leukaemic effects of ectopic LMO2.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2006 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2006 Tipo de documento: Article